Respiration failure type 2 is loss of the lungs ability to take up oxygen (O2) and get rid of carbon dioxide (CO2). The diagnosis is based on blood gas measurement of pressures of O2 and CO2. Patients with COPD is often seen to have co-morbidity with cardiac diseases. Chronic systemic inflammation is seen in both COPD and cardiac diseases. The investigators will investigate the sleep quality, CO2-retention, O2-saturation, cardiac arrythmias and markers of inflammation in 120 patients with COPD in different stages of the disease. Our hypotheses are: * that the first signs of respiration failure type 2 is seen during sleep with alteration of sleep patterns and greater and more long-lasting retention of CO2 in the blood compared to those with a normal lung function * that the use of alcohol, zopiclone or supplementary oxygen will make these differences even greater * that cardiac arrythmias correlates with hypoxemia * that cardiac arrythmias and respiration failure correlates with degree of inflammation
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
150
Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
5 mg sedative given approximately 1 hour before sleep
5 mg alcohol/kg body-weight approximately 1 hour before sleep
Glittreklinikken
Hakadal, Akershus, Norway
Glittreklinikken
Oslo, Hakadal, Norway
transcutaneously measured pCO2 during sleep
Time frame: 1 year
cardiac arrythmias registered by Holter monitoring
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.